Teva’s Huntington’s Drug Application Approved By FDA

August 13, 2015 | Teva Pharmaceutical Industry’s new drug application for Huntington’s Disease medication was approved by the US Food & Drug Administration. The drug, SD-809, was approved for the treatment of chorea, a neurological disorder associated with Huntington’s Disease. The trial drug SD-809 was added to Teva’s portfolio after the pharmaceutical company acquired Auspex for $3.2 billion in May 2015. Teva was founded in 1901 and is headed by CEO Erez Vigodman.